We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The 11-member committee voted to recommend the drug based on data from a multicenter trial. The overall response rate was 15 percent, with an overall survival of 82.4 weeks. Read More
The approval of Novartis’ novel gene therapy Zolgensma was one of CBER’s major achievements in fiscal 2019, according to center Director Peter Marks. Read More